ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML


Study Number
497719
Phase
I
Age Group
Adult
Purpose

This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in lymphoid blast crisis. BCR-ABL+ B-ALL is also called Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL). It is expected that 25-34 people will take part in this research study. - ABL001 - Dasatinib (Sprycel®) - Prednisone

Full Title

A Phase 1 Study of ABL001 in combination with dasatinib and prednisone in patients with BCR-ABL positive (BCR-ABL+) B-cell acute lymphoblastic leukemia (B-ALL) and chronic myeloid leukemia (CML)

ClinicalTrials.Gov ID
NCT03595917

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.